Materials and Methods
BONE LESIONS
The BEIBI (Bioactive glass vErsus allograft for BenIgn Bone lesIons) trial was a pragmatic multicenter randomized controlled trial comparing the use of bioactive glass and allograft as filling material after curettage of benign bone lesions in children. The study centers were 4 university hospitals in a Scandinavian country. The trial was registered at ClinicalTrials.gov (NCT04737590) and was approved by the Ethics Committees of the University Hospital (ETMK 53/180/2012). Written informed consent from patients or their caregivers was required for participation. This manuscript adheres to the CONSORT (Consolidated Standards of Reporting Trials) guidelines